Pelvic Floor and Hormones: The Connection Most Women Miss

Very few women bring this up unprompted. Leaking on a run, urgency that dictates where you sit in a room, sex that has become something to get through rather than want, a third course of antibiotics in a year — these get filed under ageing, or under childbirth, and endured. The filing is wrong in an important way. Most of it is driven by a hormonal change in a specific tissue, it is progressive if left alone, and the first-line treatment is one of the safest interventions in menopausal medicine.

Why this tissue depends on oestrogen more than most

The vagina, vulva, urethra, bladder trigone and the connective tissue supporting all of it develop from shared embryological origins and share something else: an unusually high density of oestrogen receptors. That is not incidental anatomy. It means these tissues are maintained by oestrogen in a way that skin on your forearm is not.

Oestrogen does four separate jobs here, and all four fail together when it falls.

• Epithelial thickness. Oestrogenised vaginal and urethral epithelium is many cell layers deep; without oestrogen it thins to a few — more fragile, more easily abraded, more easily colonised.
• Collagen and elastin in the supporting connective tissue. Less of both means less recoil in the tissue holding the urethra in position.
• Blood flow. Vascular tone here is oestrogen-dependent, and lubrication during arousal is a transudate driven by that flow, not a gland secretion. Less flow, less lubrication, regardless of desire.
• The microbiome. Oestrogen drives glycogen deposition; lactobacilli turn that glycogen into lactic acid, which keeps vaginal pH acidic and suppresses uropathogens. No oestrogen, no glycogen, no lactobacilli, and pH rises toward neutral.

That last chain is the one most people have never heard, and it is the direct explanation for recurrent urinary infections after menopause. It is not bad luck or poor hygiene. The chemical defence has been switched off upstream.

The cluster, and why it has a name

These symptoms were called "vaginal atrophy" for decades, which described one tissue and one consequence. The term was replaced by genitourinary syndrome of menopause precisely because the urinary and sexual components are part of the same process and were being treated by different specialists who were not talking to each other (Portman et al., Menopause 2014).

What it covers:

• Stress incontinence — leaking with cough, sneeze, lifting or impact, as urethral closure pressure and support fall
• Urgency and frequency, including nocturia, from a thinned and irritable trigone
• Recurrent urinary tract infections, via the pH and lactobacilli chain above
• Painful intercourse, from thin, dry, poorly elastic tissue that tears at the introitus
• Dryness, itching and burning that are present without any sexual activity at all
• Pelvic organ prolapse or a sense of heaviness, as connective tissue support weakens
• Reduced libido, which is partly hormonal and partly a rational response to discomfort

Why it does not settle on its own

This is the single most important difference between GSM and the other menopausal symptoms, and the reason waiting is a poor strategy.

Hot flushes are vasomotor instability, and for most women they eventually burn out. GSM does not. It is a tissue state maintained by a hormone that is not coming back, so it persists and slowly worsens. A pain-avoidance loop layers on top: discomfort leads to less activity, less activity means less blood flow and more narrowing, and the pelvic floor then guards reflexively — adding a hypertonic component to what began as a purely atrophic one. Ten years of quietly putting up with it is not ten years of the same problem. It is a problem that has been compounding.

Local vaginal oestrogen, and why it is a different decision

This is the most under-used intervention in menopausal care, and the reason is a misapplied fear. Local oestrogen goes directly to the tissue that needs it, at a fraction of systemic exposure, with minimal absorption once the epithelium has restored itself.

That distinction matters clinically, because it means local treatment is available to many women for whom systemic hormone therapy is not on the table — including, per current oncology guidance, many breast cancer survivors after discussion with their oncologist (Carter et al., J Clin Oncol 2018). It is a different risk conversation from systemic HRT, and it should not be collapsed into it. Whether it is appropriate in any individual case, particularly with a cancer history, is a decision for the treating physician.

Onset is not immediate. Epithelium takes weeks to rebuild, glycogen returns after that, and the microbiome follows. Most women notice change over roughly four to eight weeks, and the urinary benefits often arrive after the vaginal ones. Evidence for the urinary side specifically is reasonable: vaginal oestrogen reduces recurrent urinary tract infections in postmenopausal women (Raz et al., N Engl J Med 1993), and pooled trial data support local oestrogen for incontinence symptoms while noting that systemic oestrogen alone does not help and may worsen them (Cody et al., Cochrane Database Syst Rev 2012).

Note that last point carefully, because it is the one that surprises people: systemic and local oestrogen are not interchangeable for urinary symptoms. More on the specifics in why vaginal oestrogen is under-used.

Where systemic HRT fits

Systemic hormone therapy is decided on its own merits — vasomotor symptoms, sleep, mood, bone, and the timing and history that govern candidacy. It is not the treatment for GSM and should not be started for GSM alone.

Where a woman is already on it, it provides background tissue support. But local concentration at the pelvic tissue is often insufficient from systemic dosing alone, which is why many women on well-managed HRT still have dryness and urinary symptoms and conclude the HRT has failed. It has not; it is treating a different problem. Using both is common and appropriate — see when to start HRT and HRT for women.

The mechanical half, which hormones do not fix

Oestrogen restores tissue quality. It does not retrain muscle, and it does not release a guarded pelvic floor.

Pelvic floor physiotherapy addresses that half: assessing whether the floor is weak, over-tight, or both; coordinating it with breathing and intra-abdominal pressure; and correcting the lifting and bracing patterns that drive symptoms during exercise. Supervised training beats no treatment for urinary incontinence with reasonable consistency across trials (Dumoulin et al., Cochrane Database Syst Rev 2018) — and the word doing the work in that sentence is supervised. Unguided Kegels are frequently performed incorrectly, and in a woman whose floor is already hypertonic, more squeezing makes things worse rather than better. This is the case where an assessment genuinely changes the prescription.

Order of operations

1. Name the problem. GSM is a clinical diagnosis; it does not require a test, only that someone asks the question.
2. Start local oestrogen if appropriate, and give it a fair trial of at least eight to twelve weeks before judging it. This is where most of the benefit comes from and it is first-line.
3. Decide systemic HRT separately, on its own indications.
4. Get a pelvic floor assessment where incontinence, prolapse or pain persists — before assuming the hormones failed.
5. Deal with the contributors. Chronic constipation, chronic cough, bracing technique under load, and caffeine and alcohol intake all load the same system.
6. Continue treatment. GSM returns when local oestrogen stops, usually within months, because the underlying hormonal state has not changed. This is maintenance, not a course.

Bottom line

Pelvic floor and genitourinary symptoms after menopause are not an inevitable cost of ageing or of having had children. They are a tissue state driven by oestrogen withdrawal, running through epithelial thinning, collagen loss, reduced blood flow and a shifted vaginal pH — which is why the sexual and urinary symptoms travel together. Unlike hot flushes, this one does not resolve on its own; it compounds. Local vaginal oestrogen is first-line, works over weeks rather than days, is a different risk conversation from systemic HRT, and needs to be continued to keep working. Pelvic floor physiotherapy handles the muscular half that hormones cannot touch. The most common failure here is not a treatment that did not work — it is a symptom that was never mentioned. The 60-second assessment is a reasonable place to start that conversation.

Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.